Genetron Holdings Ltd
NASDAQ:GTH
Intrinsic Value
Genetron Holdings, Ltd. engages in precision oncology. [ Read More ]
The intrinsic value of one
GTH
stock under the Base Case scenario is
6.4926
USD.
Compared to the current market price of 4.0201 USD,
Genetron Holdings Ltd
is
Undervalued by 38%.
Genetron Holdings Ltd's market capitalization is 127.1m USD.
GTH stock price is 4.0201 USD.
GTH stock price (4.0201 USD) is 38% less than its Intrinsic Value (6.4926 USD).
GTH. Open DCF Valuation
GTH stock price (4.0201 USD) is 38% less than its Relative Value (6.4926 USD). Open Relative Valuation
GTH has downside potential of 67% compared to the average analyst price target.
Open Wall St Estimates
GTH's Revenue has grown by an exceptional 22% over the past 12 months.
GTH's short-term assets (709m CNY) exceed its short-term liabilties (390m CNY).
GTH's ROE (Return on Equity) has significantly decreased in the last 3 years from 3 326% to -92%.
GTH's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -128% to -155%, and is approaching profitability.
GTH's long-term assets (975m CNY) exceed its long-term liabilties (429m CNY).
GTH has negative Operating Income for the last twelve months.
GTH has negative Net Income for the last twelve months.
GTH's ROE (Return on Equity) for the past 12 months is negative and is equal to -92%.
GTH's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -155%.
GTH has positive Gross Profit for the last twelve months.
GTH has negative Free Cash Flow for the last twelve months.
GTH's D/E (Debt to Equity) is very low and is equal to 0.05.
GTH has very high three-year average ROE (Return on Equity): 640%. The company is very efficient at transforming stockholders' equity into net income.
GTH has negative three-year average ROIC (Return on Invested Capital): -152%. The company is not efficient at using invested capital to generate operating income.
GTH has negative Net Debt. This means that the company has more cash and short-term investments (334m CNY) than debt (27m CNY).
GTH's Altman Z-Score is very low and is equal to -10.47.
GTH doesn't generate enough operating income (-704m CNY) to safely cover interest payments on its debt (5m CNY).
Valuation Backtest
Genetron Holdings Ltd
Run backtest to discover the historical profit from buying and selling
GTH
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
This note will be permanently deleted.
Genetron Holdings Ltd
Balance Sheet Decomposition
Genetron Holdings Ltd
| Current Assets | 709m |
| Cash & Short-Term Investments | 333.7m |
| Receivables | 323.4m |
| Other Current Assets | 51.9m |
| Non-Current Assets | 266.3m |
| Long-Term Investments | 50.5m |
| PP&E | 177.6m |
| Intangibles | 32.1m |
| Other Non-Current Assets | 6.1m |
| Current Liabilities | 389.9m |
| Accounts Payable | 249m |
| Other Current Liabilities | 140.9m |
| Non-Current Liabilities | 39.3m |
| Long-Term Debt | 27.3m |
| Other Non-Current Liabilities | 12m |
Earnings Waterfall
Genetron Holdings Ltd
|
Revenue
|
650.7m
CNY
|
|
Cost of Revenue
|
-369.3m
CNY
|
|
Gross Profit
|
281.4m
CNY
|
|
Operating Expenses
|
-985m
CNY
|
|
Operating Income
|
-703.6m
CNY
|
|
Other Expenses
|
-104.8m
CNY
|
|
Net Income
|
-808.4m
CNY
|
Free Cash Flow Analysis
Genetron Holdings Ltd
| CNY | |
| Free Cash Flow | CNY |
GTH Profitability Score
Profitability Due Diligence
Genetron Holdings Ltd's profitability score is 34/100. The higher the profitability score, the more profitable the company is.
Score
Genetron Holdings Ltd's profitability score is 34/100. The higher the profitability score, the more profitable the company is.
GTH Solvency Score
Solvency Due Diligence
Genetron Holdings Ltd's solvency score is 47/100. The higher the solvency score, the more solvent the company is.
Score
Genetron Holdings Ltd's solvency score is 47/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
GTH Price Targets Summary
Genetron Holdings Ltd
According to Wall Street analysts, the average 1-year price target for
GTH
is 1.34 USD
.
Shareholder Return
GTH Price
Genetron Holdings Ltd
| Average Annual Return | -50.69% |
| Standard Deviation of Annual Returns | 34.34% |
| Max Drawdown | -98% |
| Market Capitalization | 127.1m USD |
| Shares Outstanding | 31 624 400 |
| Percentage of Shares Shorted | 0.32% |
Company Profile
Genetron Holdings Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Genetron Holdings, Ltd. engages in precision oncology. The company is headquartered in Beijing, Beijing. The company went IPO on 2020-06-19. The firm has developed a comprehensive product and service portfolio that cover the full-cycle of cancer care from early screening, to diagnosis and treatment recommendations, to continuous monitoring and continuous care. The firm operates its businesses primarily within the China market.
Contact
IPO
Employees
Officers
The intrinsic value of one
GTH
stock under the Base Case scenario is
6.4926
USD.
Compared to the current market price of 4.0201 USD,
Genetron Holdings Ltd
is
Undervalued by 38%.
You don't have any saved screeners yet
